Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Mi | Creative Medical Technology Holdings, Inc.: Creative Medical Technology Holdings Secures FDA Fast Track Designation for CELZ-201-DDT - Advancing Breakthrough Therapy for Chronic Lower Back Pain | 63 | GlobeNewswire (Europe) | PHOENIX, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ), a clinical-stage biotechnology company focused on regenerative and immune cellular therapies,... ► Artikel lesen | |
08.08. | CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
17.07. | Creative Medical receives patent allowance for diabetes treatment | 5 | Investing.com | ||
17.07. | Creative Medical Technology Holdings, Inc.: Creative Medical Technology Holdings Receives Notice of Allowance for the Prevention and/or Treatment of Type 1 Diabetes Using Modulated Immune Cells | 1 | GlobeNewswire (USA) | ||
11.07. | Creative Medical Technology Holdings, Inc.: Creative Medical Technology Holdings Receives Notice of Allowance for ImmCelz for Treatment of Heart Failure and/or Post Infarct Pathological Remodeling | 233 | GlobeNewswire (Europe) | PHOENIX, July 11, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) ("Creative Medical" or the "Company"), a clinical-stage biotechnology company specializing in regenerative... ► Artikel lesen | |
CREATIVE MEDICAL TECHNOLOGY Aktie jetzt für 0€ handeln | |||||
09.05. | CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
06.05. | CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
25.04. | CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. - 10-K/A, Annual Report | 1 | SEC Filings | ||
04.04. | CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. - 10-K/A, Annual Report | 1 | SEC Filings | ||
02.04. | Creative Medical Technology files to sell 1.8M shares of common stock by selling shareholders | 2 | Seeking Alpha | ||
20.03. | Creative Medical Technology Holdings, Inc.: Creative Medical Technology Holdings Secures FDA Clearance for Expanded Dose Escalation in the Clinical Trial of CELZ-201-DDT for Chronic Lower Back Pain | 104 | GlobeNewswire (Europe) | PHOENIX, March 20, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) (the "Company"), a clinical-stage biotechnology company specializing in regenerative medicine... ► Artikel lesen | |
19.03. | CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. - 10-K/A, Annual Report | 1 | SEC Filings | ||
14.03. | CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
14.03. | CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. - 10-K, Annual Report | 1 | SEC Filings | ||
07.03. | CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. - 8-K, Current Report | - | SEC Filings | ||
06.03. | Creative Medical Technology sichert sich 3,7 Millionen US-Dollar durch Optionsscheine | 7 | Investing.com Deutsch | ||
06.03. | Creative Medical Technology secures $3.7 million through warrants | 1 | Investing.com | ||
06.03. | Creative Medical Technology Holdings, Inc.: Creative Medical Technology Holdings Announces Agreements for Exercise of Warrants for $3.7 Million Gross Proceeds | 1 | GlobeNewswire (USA) | ||
14.02. | Creative Medical Technology Holdings, Inc.: Creative Medical Technology Holdings Announces Mid-Term Follow-up Study Data Reporting Significant Reduction in Opioid Use by Chronic Lower Back Pain Patients Undergoing StemSpine ... | 159 | GlobeNewswire (Europe) | PHOENIX, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. ("Creative Medical Technology" or the "Company") (NASDAQ: CELZ), a pioneering biotechnology firm specializing... ► Artikel lesen | |
11.02. | Creative Medical Technology Holdings, Inc.: Creative Medical Technology Reports Positive One-Year Results for AlloStem Type 2 Diabetes Program | 158 | GlobeNewswire (Europe) | PHOENIX, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ), a clinical-stage biotechnology company advancing regenerative medicine solutions, today announced... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
QIAGEN | 41,960 | -0,24 % | JEFFERIES stuft QIAGEN NV auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat das Kursziel für Qiagen nach Zahlen von 54 auf 57 US-Dollar angehoben und die Einstufung auf "Buy" belassen. Tycho Peterson attestierte dem... ► Artikel lesen | |
EVOTEC | 6,356 | -2,37 % | Plattform-Strategien krempeln Biotech-Markt um: BioNxt, Thermo Fisher Scientific, Evotec | Bei Biotech gilt längst nicht mehr das Prinzip alles oder nichts. Statt nur ein Produkt im Angebot zu haben, setzt sich bei der Entwicklung der Wirkstoffe von morgen die Plattform-Ökonomie durch. Was... ► Artikel lesen | |
DYNE THERAPEUTICS | 12,380 | -1,12 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-251 in Duchenne Muscular Dystrophy (DMD) | - Data from the DELIVER registrational expansion cohort is expected in late 2025, with a potential BLA submission for U.S. accelerated approval anticipated in early 2026 - WALTHAM, Mass., Aug.... ► Artikel lesen | |
AVIDITY BIOSCIENCES | 46,550 | +1,00 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Second Quarter 2025 Financial Results and Recent Highlights | Aligned with FDA on del-brax accelerated and full approval pathways for FSHD, reported positive topline data from Phase 1/2 FORTITUDE trial, and initiated global... ► Artikel lesen | |
BOLT PROJECTS | 8,910 | +4,82 % | Pre-market Movers: Sonoma Pharmaceuticals, Bolt Projects, Ibotta, TeraWulf, 180 Life Sciences | BRASILIA (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 08.50 A.M. ET).In the Green Sonoma Pharmaceuticals, Inc. (SNOA) is up over... ► Artikel lesen | |
BIONTECH | 97,00 | -0,05 % | EQS-News: CureVac kündigt Einigung zur Beilegung des Patentstreits mit Pfizer/BioNTech an | Emittent / Herausgeber: CureVac
/ Schlagwort(e): Patent
CureVac kündigt Einigung zur Beilegung des Patentstreits mit Pfizer/BioNTech an
08.08.2025 / 02:15 CET/CEST
Für... ► Artikel lesen | |
ITEOS THERAPEUTICS | 10,105 | -0,05 % | iTeos Therapeutics Inc.: iTeos Therapeutics Enters into Agreement to Be Acquired by Concentra Biosciences for $10.047 in Cash per Share Plus a Contingent Value Right | WATERTOWN, Mass. and GOSSELIES, Belgium, July 21, 2025 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. ("iTeos") (Nasdaq: ITOS) today announced that it has entered into a definitive merger agreement... ► Artikel lesen | |
VALNEVA | 4,730 | -0,76 % | Rheinmetall: Schwach, aber... - Bayer, Commerzbank, Deutz, ThyssenKrupp und Valneva im Marktbericht Börse Frankfurt | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
IMMUNOME | 10,280 | +3,32 % | Immunome Inc. - 10-Q, Quarterly Report | ||
ARS PHARMACEUTICALS | 14,540 | +0,48 % | ARS Pharmaceuticals stock maintains Strong Buy rating at Raymond James on strong neffy sales | ||
RECURSION PHARMACEUTICALS | 5,765 | +2,22 % | Recursion Pharmaceuticals: Recursion Reports Second Quarter 2025 Financial Results and Provides Business Update | SALT LAKE CITY, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and... ► Artikel lesen | |
SUMMIT THERAPEUTICS | 26,690 | +0,91 % | Summit Therapeutics: Ivonescimab Data from Global Phase III HARMONi Study to be Showcased at Presidential Symposium at WCLC 2025 | Ivonescimab to be Featured at WCLC Presidential Symposium for Second Consecutive Year
Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that data from the... ► Artikel lesen | |
VIR BIOTECHNOLOGY | 4,520 | +1,80 % | Vir Biotechnology, Inc.: Vir Biotechnology Announces Preliminary 24-Week Post-End of Treatment Data for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B From the MARCH Study | HBsAg loss 24 weeks post-end of treatment achieved in 17% and 21% of participants with low baseline HBsAg receiving tobevibart elebsiran without or with PEG-IFNa, respectively As previously... ► Artikel lesen | |
LENZ THERAPEUTICS | 37,870 | -7,43 % | LENZ Therapeutics, Inc.: LENZ Therapeutics and Lotus Pharmaceutical Announce Exclusive License and Commercialization Agreement for LNZ100 in the Republic of Korea and Southeast Asia | SAN DIEGO and TAIPEI, Taiwan, May 09, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ) and Lotus Pharmaceutical Co., Ltd. ("Lotus", TWSW Stock Code: 1795) today announced an exclusive... ► Artikel lesen | |
FULCRUM THERAPEUTICS | 6,820 | +3,33 % | Fulcrum Therapeutics, Inc.: Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | CAMBRIDGE, Mass., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives... ► Artikel lesen |